Zhu Menglan, Jin Wenyu, He Wangbiao, Zhang Lulu
Sanitation Teaching and Research Section of Department of Health Service, Naval Medical University, Shanghai, China.
Otolaryngology Department of Unit 32265 of the People's Liberation Army, Guangzhou, China.
Front Cardiovasc Med. 2024 Sep 18;11:1408487. doi: 10.3389/fcvm.2024.1408487. eCollection 2024.
Cardiovascular diseases (CVDs) are not only the primary cause of mortality in China but also represent a significant financial burden. The World Health Organization highlight that as China undergoes rapid socioeconomic development, its disease spectrum is gradually shifting towards that of developed countries, with increasing prevalence of lifestyle-related diseases such as ischemic heart disease and stroke. We reviewed the rates and trends of CVDs incidence, mortality and disability-adjusted life years (DALYs) burden in China and compared them with those in the United States (US) and Japan for formulating CVDs control policies.
Data on CVDs incidence, death and DALYs in China, the US and Japan were obtained from the GBD 2019 database. The Joinpoint regression model was used to analyze the trends in CVDs incidence and mortality in China, the US and Japan, calculate the annual percentage change and determine the best-fitting inflection points.
In 2019, there were approximately 12,341,074 new diagnosed cases of CVDs in China, with 4,584,273 CVDs related deaths, causing 91,933,122 DALYs. The CVDs age-standardized incidence rate (ASIR) in China (538.10/100,000) was lower than that in the US and globally, while age-standardized death rate (ASDR) (276.9/100,000) and age-standardized DALY rate (6,463.47/100,000) were higher than those in the two regions. Compared with the US and Japan, from 1990 to 2019, the CVDs incidence rate in China showed an increasing trend, with a lower annual decrease in ASDR and a younger age structure of disease burden. Furthermore, the disease spectrum in China changed minimally, with stroke, ischemic heart disease, and hypertensive heart disease being the top three leading CVDs diseases in terms of incidence and disease burden, also being the major causes of CVDs in the US and Japan.
The prevention and control of CVDs is a global issue. The aging population and increasing unhealthy lifestyles will continue to increase the burden in China. Therefore, relevant departments in China should reference the established practices for CVDs control in developed countries while considering the diversity of CVDs in different regions when adjusting national CVDs control programs.
心血管疾病(CVDs)不仅是中国的主要死因,还带来了巨大的经济负担。世界卫生组织强调,随着中国社会经济的快速发展,其疾病谱正逐渐向发达国家转变,与生活方式相关的疾病如缺血性心脏病和中风的患病率不断上升。我们回顾了中国心血管疾病的发病率、死亡率和伤残调整生命年(DALYs)负担的变化率及趋势,并将其与美国和日本进行比较,以制定心血管疾病控制政策。
中国、美国和日本心血管疾病的发病率、死亡率和DALYs数据来自全球疾病负担研究(GBD)2019数据库。采用Joinpoint回归模型分析中国、美国和日本心血管疾病发病率和死亡率的趋势,计算年度变化百分比并确定最佳拟合拐点。
2019年,中国新诊断心血管疾病病例约12341074例,心血管疾病相关死亡4584273例,导致91933122个伤残调整生命年。中国心血管疾病年龄标准化发病率(ASIR)(538.10/10万)低于美国和全球水平,而年龄标准化死亡率(ASDR)(276.9/10万)和年龄标准化DALY率(6463.47/10万)高于这两个地区。与美国和日本相比,1990年至2019年,中国心血管疾病发病率呈上升趋势,年龄标准化死亡率年下降幅度较小,疾病负担的年龄结构更年轻。此外,中国的疾病谱变化最小,中风、缺血性心脏病和高血压性心脏病在发病率和疾病负担方面是心血管疾病的三大主要类型,也是美国和日本心血管疾病的主要原因。
心血管疾病的预防和控制是一个全球性问题。人口老龄化和不健康生活方式的增加将继续加重中国的负担。因此,中国相关部门在调整国家心血管疾病控制计划时,应借鉴发达国家既定的心血管疾病控制做法,同时考虑不同地区心血管疾病的多样性。